Mirabella Financial Services LLP Lineage Cell Therapeutics, Inc. Transaction History

Mirabella Financial Services LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.02 - $1.5 $75,546 - $111,097	74,065 New	74,065 $86,000
Q2 2022 Aug 12, 2022	SELL	$1.12 - $1.61 $21,056 - $30,268	-18,800 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.21 - $2.48 $22,748 - $46,624	18,800 New	18,800 $29,000
Q1 2021 May 17, 2021	SELL	$1.77 - $3.1 $109,129 - $191,130	-61,655 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $58,572 - $112,828	61,655 New	61,655 $109,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Mirabella Financial Services LLP, based on Form 13F filings with the SEC.

Stay updated on Mirabella Financial Services LLP with notifications on news.